Cargutocin is an uterotonic. It is Oxytocin analog and it targets oxytocin receptor. Oxytocic activity in pregnant rats and rabbits was weak in comparison with oxytocin.

Flucloronide is a glucocorticoid. Fluclorolone acetonide is used for the palliative treatment of psoriasis and skin diseases.

Mestanolone is an oral analogue of dihydrotestosterone. This steroid is a 17-alpha methylated form of this potent endogenous androgen, being essentially (in structure) to dihydrotestosterone what methyltestosterone is to testosterone. Overall, mestanolone has an activity profile not very dissimilar from the hormone it is derived from. Like dihydrotestosterone, mestanolone is primarily androgenic in nature, displaying a low level of anabolic activity. Both dihydrotestosterone and mestanolone are also devoid of estrogenic activity. Dihydrotestosterone was synthesized in 1935. After that 17-alpha-methylated version also appeared. This steroid was not frequently used in clinical medicine. It was produced under the name of ermalon for short period of time. Most studies involving mestanolone were carried out in the 1950s and 1960s. In the 1970s and 1980s it was used as part of the East German doping machine. Mestanolone was evaluated not for its anabolic ability but for its androgenic essence. It improved the functioning of the CNS and neuromuscular interaction. Athletes claimed that it did not make them huge, but gave them speed, strength, aggression, stamina and resistance to stress. Mestanolone is still valued as an oral androgen.

Normethandrone (Orgasteron; Metalutin; Methalutin) is a progestin and androgen/anabolic steroid agent which is used in combination with an estrogen in the treatment of menstruation disorders in women. Normethandrone is a modified form of nandrolone. It differs by the addition of a methyl group at carbon 17-alpha to protect the hormone during oral administration. Normethandrone is aromatized by the body, and converts to a synthetic estrogen with a high level of biological activity (17alpha-methyl-estradiol). Orgasteron has been used as progestational agent and as an androgen. Normethandrone is available in combination with methylestradiol or estradiol valerate in a few countries, including Brazil, Indonesia, and Venezuela. This is a controlled substance (anabolic steroid): 21 CFR, 1308.13, as defined in 1300.01. Normethandrone was first described in 1954. Shortly after, it was developed into a medicine by Organon (now Merck/MSD), which introduced it under the Orgasterone brand name in Belgium and Switzerland, and as Orgasteron in the Netherlands. This steroid had also been sold by other manufacturers in various parts of Europe as Methalutin, Lutenin, and Matdonal. Although a simple oral methylated nandrolone, with strong properties as an anabolic steroid, Normethandrone exhibits such strong progestational activity that it was marketed as an oral progestin. Its anabolic effects were more looked at as secondary applications for the drug, and accounted for very little medical interest.

Amebucort is a synthetic glucocorticoid corticosteroid for topical application which was never marketed. Amebucort may used for the research of inflammatory disorders

Subarachnoid haemorrhage (SAH) following cerebral aneurysm rupture or trauma can result in the induction of secondary ischaemic brain damage via a decrease in microvascular perfusion, a disruption of the blood-brain barrier and consequent vasogenic oedema, and the delayed spasm of the major cerebral arteries (i.e. vasospasm). It is increasingly apparent that oxygen radical-induced, iron-catalyzed lipid peroxidation (LP) within the subarachnoid blood and vascular wall plays a key role in the occurrence of these secondary events. Tirilazad mesylate, is a nonglucocorticoid, 21-aminosteroid, is a potent cytoprotective inhibitor of LP that works by a combination of radical scavenging and membrane stabilizing properties. It has been demonstrated to attenuate the acute and delayed vascular consequences of SAH and to protect the brain against ischaemic insults. Tirilazad mesylate has been proposed to treat acute ischaemic stroke. When tested on animal models, tirilazad protects brain tissue, and reduces brain damage. However, the drug fails to treat, and even worsens a stroke when studied on a human being.

Butixocort, also known as tixocortol butyrate, is a synthetic locally acting thioester-linked corticosteroid glucocorticoid corticosteroid with potent anti-inflammatory activity developed by Jouveinal for treatment Allergic rhinitis and Asthma. Butixocort characterized by a large dissociation between it’s local and systemic effects; Butixocorts low or nonexistent glucocorticoid side effects are explained by its high systemic metabolic clearance. The dissociation between local activity and systemic side effects of Butixocorts has been found to be between 100 and 1000 times higher than those of beclomethasone dipropionate and budesonide.

Fluprednidene (used in a form of fluprednidene 21-acetate) is a glucocorticoid developed for the treatment of inflammatory skin diseases. The drug is marketed under the name Decoderm in Europe.

Azetirelin (also known as YM-14673), a new thyroid-releasing hormone (TRH) analog, which was participated in clinical trials phase III in Japan for the treatment of cerebrovascular disorders and of neurological disorders.

Bolandiol is an anabolic-androgenic steroid that was never marketed. A dipropionate ester, bolandiol dipropionate (brand names Anabiol, Storinal; former developmental code name SC-7525), has been marketed. Bolandiol dipropionate is an androgen receptor agonist. Research has shown the enhancing effect of Anabiol on hepatocarcinogenesis.